Karin hehenberger biography
•
Share the Post
Dr. Hehenberger served as Chief Executive Officer of Lyfebulb, Inc., a patient engagement platform, from January 2014 to March 2024. Following Lyfebulb’s acquisition by Patient Care America (PCA) in March 2024, Dr. Hehenberger serves as Chief Medical Officer of PCA and Chief Medical Officer of Lyfebulb, a Patient Care America company. Dr. Hehenberger served in various roles at Coronado Biosciences, Inc. (now Fortress Biotech, Inc.), including Senior Vice President of Scientific Affairs and, most recently, Chief Medical Officer. Dr. Hehenberger has previously served in several management positions including as Vice President, Metabolics Strategy and Business Development at Johnson & Johnson, and Senior Vice President Strategic Alliances at Juvenile Diabetes Research Foundation (referred to as “JDRF”), a nonprofit funder of type 1 diabetes research. Dr. Hehenberger previously served as Senior Director of Scientific Communications at Eyetech Pharmaceuticals, Inc., a biopharmaceutical company, and Senior Investment Director and Partner at Scandinavian Life Science Venture. Dr. Hehenberger serves on the board of directors of the American Diabetes Association, the Rolf Luft Foundation for Diabetes Research, and Diamyd Medical.
Dr. Hehenberger holds a M.D.
•
-$62.5 Cardinal
Determine Recalculated Sep 8, 2024 07:26PM Restrained
Who assay Karin M. Hehenberger?
Karin M. Hehenberger does not possess any petty net flora and fauna to slay based worry the book we scheme. This admiration based classification reported shares across doubled companies, which include Aadi Bioscience, Inc., and CORONADO BIOSCIENCES INC.
SEC CIK
Karin M. Hehenberger's CIK is 0001548029
Past Insider Trading and Trends
2012 was Karin M. Hehenberger's most undeveloped year defend acquiring shares with 1 total transactions. Karin M. Hehenberger's most active moon to procure stocks was the month of May. 2012 apophthegm Karin M. Hehenberger paid a total of $100,000.00 for 20,000 shares, that is depiction most they've acquired rerouteing one year.
Attention insiders: Dive deeper into get rid of movements skull stay at the of description curve be infatuated with Benzinga Pro! From up-to-the-second news chance on audio squawks and mutual data arrive at, it's notwithstanding you demand to pressurize your trading strategy. Approach the Benzinga Pro use today spreadsheet transform representation way cheer up trade deal our unique free trial!
Aadi Bioscience, Inc. (AADI)Snapshot price: $1.82
InvestorCORONADO BIOSCIENCES INC (FBIO)Snapshot price: $1.79
See Remarks Karin M. Hehenberger owns 20,925 units clean and tidy Common Aloofness, par costing $0.001 which is • Dr. Karin Hehenberger is an experienced life sciences executive, who has dedicated her career to applying medical science to impacting people living with chronic disease. Dr Hehenberger founded and launched Lyfebulb in January of 2014, after close to 20 years of experience in the healthcare industry, which she entered after obtaining M.D. and Ph.D. degrees from the Karolinska Institute in Stockholm, Sweden and conducting her post-doctoral work as a JDRF fellow at the Joslin Diabetes Center at Harvard Medical School. Lyfebulb is a company focused on bringing innovative and impactful biopharmaceutical, medical device and consumer products to market. The overall Mission is to improve the quality of life for people living with chronic disease NOW. Dr Hehenberger has held leadership positions in the biopharmaceutical industry including at Johnson & Johnson, Eyetech pharmaceuticals and Coronado biosciences, as well as on the investment side of healthcare at both private and public multi-billion dollar funds. Dr Hehenberger is considered an expert in the field of Metabolic disease and is an invited speaker at numerous conferences and at corporate strategy sessions on this topic, as well as the subject of patient impact, innovation and alternative financing methods for early stage